Drug Profile
Research programme: cancer and cardiovascular disorder therapies - Jina Pharmaceuticals
Alternative Names: JIN2011; JIN2013; JIN2019Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Jina Pharmaceuticals
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Cardiovascular disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in Unknown (IV)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cardiovascular-disorders in Unknown (IV)
- 18 May 2012 Preclinical trials in Cancer (IV)